Handelsman, Yehuda Muskiet, Marcel H. A. Meneilly, Graydon S.
Published in
Advances in Therapy
AbstractEstimates suggest that there are currently 122.8 million adults 65–99 years of age living with diabetes, of whom 90–95% are diagnosed with type 2 diabetes (T2D). Over the past two decades, a greater understanding of the complex and multifactorial pathogenesis of T2D has resulted in the development and introduction of new-generation classes ...
Adelman, Daphne T. Van Genechten, Dirk Megret, Clémentine M. Truong Thanh, Xuan-Mai T. Hand, Philippa Martin, Wendy A.
Published in
Advances in Therapy
IntroductionAlthough the previous lanreotide autogel/depot syringe had been well received, feedback indicated that improvements could be made to make it more user-friendly. Additionally, the view that patients should have greater involvement in the research and development process is echoed by the International Neuroendocrine Cancer Alliance. A ser...
Spannella, Francesco Giulietti, Federico Di Pentima, Chiara Sarzani, Riccardo
Published in
Advances in Therapy
IntroductionWe evaluated the prevalence and control of dyslipidemia in a wide sample of patients referred to our ESH “Hypertension Excellence Centre” for high blood pressure (BP). Furthermore, we evaluated the role of adiposity on the serum lipid profile.MethodsObservational study on 1219 consecutive outpatients with valid ambulatory BP monitoring ...
Rajappa, Senthil Krishna, M. Vamshi Narayanan, Prasad
Published in
Advances in Therapy
Treatment of non-small cell lung cancer (NSCLC) is evolving with the use of precision medicine for patients with sensitizing epidermal growth factor receptor (EGFR) mutation. First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) remained the standard of care for patients with EGFR-mutated advanced NSCLC for about a decade. However, tr...
Akizawa, Tadao Iwasaki, Manabu Otsuka, Tetsuro Reusch, Michael Misumi, Toshihiro
Published in
Advances in Therapy
IntroductionThis study evaluated efficacy and safety/tolerability of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis-dependent chronic kidney disease (NDD-CKD) patients.MethodsIn this phase 2, double-blind, 24-week study, NDD-CKD patients were randomized to oral placebo or roxadustat (50, 7...
Langworthy, Michael J. Conaghan, Philip G. Ruane, Joseph J. Kivitz, Alan J. Lufkin, Joelle Cinar, Amy Kelley, Scott D.
Published in
Advances in Therapy
IntroductionOsteoarthritis (OA) is common and its prevalence is increased in military service members. In a phase 3 randomized controlled trial (NCT02357459), a single intra-articular injection of an extended-release formulation of triamcinolone acetonide (TA-ER) in participants with unilateral or bilateral knee OA demonstrated substantial improvem...
Ho, Bing Bhagat, Hardik Schwartz, Jason J. Atiemo, Kofi Daud, Amna Kang, Raymond Montag, Samantha E. Zhao, Lihui Lee, Edward Skaro, Anton I.
...
Published in
Advances in Therapy
IntroductionReal-world data with extended-release tacrolimus (ER-T) are lacking in the USA. This study examined clinical outcomes and healthcare resource utilization in kidney transplant patients receiving ER-T in clinical practice.MethodsThis was a retrospective, single-center analysis (February–June 2016) using data from Northwestern University’s...
Chang, Chiung-Chih Peng, Giia-Sheun Lai, Te-Jen Li, Chien-Hsun Liu, Ching-Kuan
Published in
Advances in Therapy
IntroductionRivastigmine is a cholinesterase inhibitor, approved for the treatment of mild-to-moderate dementia of Alzheimer’s type. This study assessed the short- and long-term effectiveness and safety of rivastigmine in patients with mild-to-moderate Alzheimer’s disease (AD) in a real-world clinical setting in Taiwan.MethodsThis was a 48-week, si...
Schey, Carina Meier, Genevieve Pan, Janice
Published in
Advances in Therapy
IntroductionMetastatic renal cell carcinoma is a complex cancer for which several drugs have been developed over the years. More recently, drugs that target the specific cancer cell mutations have been developed for metastatic cell carcinoma. However, even with the recent influx of targeted therapy options, significant unmet needs exist in around h...
Zhao, Hongxin Ning, Yi Cooper, James Refoios Camejo, Rodrigo Ni, Xiajun Yi, Bingming Parks, Daniel
Published in
Advances in Therapy
IntroductionTo evaluate the comparative efficacy and safety of ropinirole and pramipexole as adjunctive therapies to levodopa (l-dopa) for the management of advanced Parkinson’s disease (PD), via a systematic review and network meta-analysis.MethodsTwenty-one double-blind randomised controlled trials of patients with advanced PD with motor fluctuat...
